奥拉帕利用于治疗转移性生殖系BRCA突变乳腺癌 - Suppr

Suppr

超能文献

Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.

作者信息

Robson Mark, Goessl Carsten, Domchek Susan

机构信息

Memorial Sloan Kettering Cancer Center, New York, NY

AstraZeneca, Gaithersburg, MD

出版信息

N Engl J Med. 2017 Nov 2;377(18):1792-3. doi: 10.1056/NEJMc1711644.

DOI:10.1056/NEJMc1711644

PMID:29091556

Abstract

摘要

相似文献

Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.

N Engl J Med. 2017 Nov 2;377(18):1792-3. doi: 10.1056/NEJMc1711644.

Olaparib for Metastatic Germline BRCA-Mutated Breast Cancer.

N Engl J Med. 2017 Nov 2;377(18):1792. doi: 10.1056/NEJMc1711644.

Olaparib tablets for the treatment of germ line BRCA-mutated metastatic breast cancer.

Expert Rev Clin Pharmacol. 2018 Sep;11(9):833-839. doi: 10.1080/17512433.2018.1513321. Epub 2018 Aug 30.

A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.

Trials. 2016 Jun 21;17(1):293. doi: 10.1186/s13063-016-1423-0.

Tumor growth inhibition by olaparib in BRCA2 germline-mutated patient-derived ovarian cancer tissue xenografts.

Clin Cancer Res. 2011 Feb 15;17(4):783-91. doi: 10.1158/1078-0432.CCR-10-1382. Epub 2010 Nov 19.

Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.

PLoS One. 2016 Dec 29;11(12):e0167272. doi: 10.1371/journal.pone.0167272. eCollection 2016.

Defective DNA repair mechanisms in prostate cancer: impact of olaparib.

Drug Des Devel Ther. 2017 Mar 1;11:547-552. doi: 10.2147/DDDT.S110264. eCollection 2017.

Germline BRCA-mutated metastatic breast cancer with positive hormone receptor.

Breast Cancer Res Treat. 2021 Feb;186(1):265-266. doi: 10.1007/s10549-020-06010-9. Epub 2020 Nov 10.

Olaparib.

Recent Results Cancer Res. 2018;211:217-233. doi: 10.1007/978-3-319-91442-8_15.

Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer.

Oncotarget. 2017 Jul 18;8(29):47154-47160. doi: 10.18632/oncotarget.17005.

引用本文的文献

USP37 counteracts HLTF to protect damaged replication forks and promote survival of BRCA1-deficient cells and PARP inhibitor resistance.

Nucleic Acids Res. 2025 Jun 20;53(12). doi: 10.1093/nar/gkaf544.

Decoding male breast cancer: epidemiological insights, cutting-edge treatments, and future perspectives.

Discov Oncol. 2025 Mar 19;16(1):360. doi: 10.1007/s12672-025-02140-y.

Hereditary Breast Cancer: Comprehensive Risk Assessment and Prevention Strategies.

Genes (Basel). 2025 Jan 13;16(1):82. doi: 10.3390/genes16010082.

Mutation Spectrum Comparison between Benign Breast Lesion Cohort, Unselected Cancer Cohort and High-Risk Breast Cancer Cohort.

Cancers (Basel). 2024 Sep 3;16(17):3066. doi: 10.3390/cancers16173066.

Predicting mutation and stratifying targeted therapy response using multimodal learning: a multicenter study.

Ann Med. 2024 Dec;56(1):2399759. doi: 10.1080/07853890.2024.2399759. Epub 2024 Sep 11.

Molecular consequences of acute versus chronic CDK12 loss in prostate carcinoma nominates distinct therapeutic strategies.

bioRxiv. 2024 Jul 19:2024.07.16.603734. doi: 10.1101/2024.07.16.603734.

A high-throughput approach to identify BRCA1-downregulating compounds to enhance PARP inhibitor sensitivity.

iScience. 2024 Jun 4;27(7):110180. doi: 10.1016/j.isci.2024.110180. eCollection 2024 Jul 19.

, and mRNA Expression as Prognostic Markers in Patients with Early Breast Cancer.

Biomedicines. 2024 Jun 19;12(6):1361. doi: 10.3390/biomedicines12061361.

Real-world data in patients with mutated breast cancer treated with poly (ADP-ribose) polymerase inhibitors.

Ecancermedicalscience. 2023 Nov 21;17:1633. doi: 10.3332/ecancer.2023.1633. eCollection 2023.

The Sensitization of Triple-Negative Breast Cancers to Poly ADP Ribose Polymerase Inhibition Independent of BRCA1/2 Mutation Status by Chemically Modified microRNA-489.

Cells. 2023 Dec 26;13(1):49. doi: 10.3390/cells13010049.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验